MedIntelliBase® NewsTips
 
Nov/Dec 2006


Your monthly newsletter from the
"better way to access market intelligence" people at medintellibase.com

MedIntelliBase NewsTips...A Better Way...to stay up-to-date


~~~Happy Holidays from MedIntelliBase!~~~
Table of Contents

Endovascular Therapeutics
  • FAST Trial - Bard Peripheral Vascular Luminexx nitinol stent
Endovascular Therapeutics
  • THUNDER Trial - Bavaria Medizin Technologie GmbH Paccocath paclitaxel coated balloons
Carotid Therapeutics & Stroke Prevention
  • PROGUARD Trial - Kensey Nash TriActiv ProGuard Embolic Protection System
Drug-eluting stents (DES) Late Thrombosis - Is there additional risk when compared to Bare Metal Stents (BMS)? Free Personal Tour - MedIntelliBase™ Alerts 
  • Sign up for your Free Personal Tour of MIB Custom Email Alerts
New MedIntelliBase™ Alerts Link of the Month
  • Nitric Oxide - Explore its role in major medical problems from cardiovascular disorders to Alzheimer's disease...
Fun Fact of the Month MedIntelliBase MarketTracks and Alerts>>
A Better Way...to Access Market Intelligence
  • MIB MarketTracks: Searchable, Easy to Use, Comprehensive Online Database
  • MIB Alerts: Convenient, Easy to Use, Customized Email Alerts
More Information Available at www.MedIntelliBase.com
Endovascular Therapeutics

FAST trial
The FAST (Femoral Artery Stenting Trial) evaluated the Bard Luminexx 3 vascular stent vs. balloon angioplasty (PTA) in 224 patients with superficial femoral artery (SFA) disease. The study's primary endpoint was binary restenosis at 12 months. FAST failed to demonstrate the superiority of the Luminexx stent over PTA in terms of the primary endpoint of binary restenosis in SFA lesions (length 1 to 10 cm). However, stent placement appeared to be associated with a tendency towards a lower risk of restenosis in a wide variety of patient and lesion subgroups, warranting further prospective randomized trials in these patient cohorts including diabetics and patients with total occlusions.

Return to Top
Endovascular Therapeutics

THUNDER trial
The THUNDER trial (Local Taxan with sHort time contact for redUctioN of restenosis in Distal artERies) evaluated the use of Bavaria Medizin Technologie GmbH Paccocath paclitaxel coated balloons in the treatment of peripheral artery disease (PAD). The study evaluated 154 patients assigned to treatment with an uncoated control balloon (n=54), an uncoated balloon + lopromid-paclitaxel (n=52), or a paclitaxel-coated balloon (n=48). Binary restenosis at 6 months was significantly reduced with the Paccocath compared to the uncoated balloon group (7/41 vs. 21/54, respectively, p<0.01). It was concluded that the Paccocath is safe and this study offered the first proof that drug-coated balloons can reduce restenosis in the treatment of SFA lesions. Follow-up is planned at 12 and 24 months.

Return to Top

Carotid Therapeutics & Stroke Prevention

PROGUARD Trial
The PROGUARD (Protection During Carotid Stenting in High Risk Patients With the TriActiv ProGuard System) trial is the phase III pivotal study for the Kensey Nash TriActiv ProGuard Embolic Protection System. The TriActiv Proguard is an embolic protection device that temporarily blocks circulation through distal and proximal balloon deployment to the lesion and clears emboli by flushing the target area. This device is already approved for use in the SFAs and studied in the PRIDE trial. The PROGUARD trial is a non-randomized, open label, single group assignment safety and efficiency trial. Expected total patient enrollment is 400.

Interested in keeping up to date on this issue? Is there another specific area of interest where you need current, timely information? Click here to learn more about our MIB Alerts and MarketTracks - A Better Way to stay up to date.

These MedIntelliBase™ MarketTracks titles are newly updated:

  • Cardiovascular (CV) Therapeutics
  • Endovascular (EV) Therapeutics
  • Carotid (Carotid) Therapeutics & Stroke Prevention
Return to Top

Drug-eluting stents (DES) - is there additional risk of late stent thrombosis when compared with bare metal stents (BMS)?

Stay tuned for our January 2007 MIB NewsTips issue for updated coverage of DES late stent thromobsis developments...

Return to Top

Free Personal Tour - MedIntelliBase™ Alerts

MIB Alerts
  • Click here and fill out the form to request your Free Personal Tour of MIB Custom Email Alerts
Return to Top

Link of the Month
  • Nitric Oxide. - Possibly best known as a pollutant found in automobile exhaust, learn about Nitric Oxide (NO) through the research of biochemist Tadeusz Malinski and his nanosensor that measures NO within the human body. [Perspectives - Ohio University]
Return to Top

Fun Fact of the Month
Return to Top

MedIntelliBase MarketTracks and Alerts >> A Better Way ...

Does this "quest for Market Intelligence" sound familiar?
  1. Search for multi-client market studies
  2. Agonize over the high prices
  3. “Bite the bullet” and purchase a report
  4. Skim the report for useful information
  5. Marvel at the lack of depth and double- or triple- spaced pages
  6. Recognize that the information in the report was only slightly out of date when the report was published - 18 months ago
  7. Spend hours trying to find the latest developments on Medline or Google
  8. Get frustrated at the inability to find what you need
  9. Write your report or your business plan that you know should be better, more in depth...if only you had better information
  10. Vow that next time, you’ll find a better way
MedIntelliBase MarketTracks and Alerts give you A Better Way:

     MIB MarketTracks

MedIntelliBase MarketTracks are searchable, comprehensive databases for specific industry segments covering new developments in clinical trials and registries, emerging technologies and products, and competing companies. MarketTracks are updated regularly and are accessible from anywhere, from any web browser. MIB MarketTracks are especially useful to Marketing, Business Development, and Research & Development executives in medical device and biotechnology companies.
  • Access your MarketTracks from anywhere >> online service
  • Packed with the latest information >> updated as new industry and late breaking trials announcements occur at major conferences***
  • Receive significantly more information than competing reports >> twice the depth & breadth of coverage
  • Easy to search >> all information in a cross-linked, searchable database
  • Fits within your budget >> competitively priced and customized subscriptions to meet your needs
  • Access online and offline >> PDF report & database search results downloadable & printable >> all included in your acquisition price
  • PLUS new this week >> More detailed market stats & projections - for Cardiovascular (CV), Endovascular (EV), & Carotid MarketTracks
***Late breaking as well as archived information on pivotal trials and registries and emerging technologies remains available to you within the MIB databases for years to come - enabling you to track years of developments and history so you and your team do not repeat past mistakes.

     MIB Alerts
MedIntelliBase Custom Email Alerts are highly flexible, customized intelligent search filters that provide convenient, timely, and specific updates on new developments within medical industry segments. MIB alerts are especially suitable for busy Marketing, Business Development, and General Management executives in medical device and biotechnology companies.
  • Easy to use >> easy-to-read and navigate alerts and archives, accessible from anywhere, from Outlook or any web browser
  • Convenient >> keep up-to-date on relevant industry events and announcements as they occur. Pushed to you via email, no need to log in for news
  • Customized >> you see only the developments that matter to you and your business
A few examples of thousands of possibilities:
  1. Peripheral Arterial Occlusion (PAO) - Thrombolysis
  2. Cardiac Structural Defects
  3. Lower Limb PAD & Atherectomy
  4. PV Angiography - Infusion Catheters
  5. CV/PV Angiography - Power Injectors
  6. Deep Vein Thrombosis (DVT) - Thrombolysis
The type of information you specify:
  • Clinical article abstracts
  • Trials and registries results
  • Preclinical article abstracts
  • Industry announcements
  • Press releases
  • Conference notices & proceedings
  • Technology developments
  • Patents issued & challenged
  • Lawsuits & other legal issues
  • FDA & voluntary product recalls
  • And more
You get much greater value from customizable MIB MarketTracks and Alerts than from standard market reports and search engines. You choose the exact depth and breadth of intelligence required, realizing the greatest value for your market intelligence money.

Click here to view a sample Custom Email Alert:

MIB Alerts

Interested? Want to know more? Want a trial?

Contact us for:
  • More information
  • Real-Time MedIntelliBase Tour
  • Free 15-Day Trial Subscription
Return to Top

More Information Available at www.MedIntelliBase.com

You can find more in-depth information about the details noted above and many other technologies and clinical studies tracked over the years at MedIntelliBase MarketTracks - visit the website at www.MedIntelliBase.com or request more information on the site.

MedIntelliBase MarketTracks and Alerts will help you find the critical intelligence you need to make informed product development and business investment decisions.

Contact MedIntelliBase directly...

Return to Top

FYI:
  1. MedIntelliBase NewsTips is free and you are welcome to continue receiving it as long as you wish. If at any time you wish to cancel just click the Safe Unsubscribe link below.
  2. We will not share your name and e-mail address with anyone.
  3. Feel free to share or reproduce the information in this MedIntelliBase NewsTips e-newsletter (in whole or part) as long as proper mention and copyright notice is given to MedIntelliBase and The Next Phase Publishing, Inc.
  4. If you are not the original recipient of this newsletter and would like to receive future issues, just click the Forward link below or drop me a line.

Editor: Vicky Hunsicker Sanko
The Next Phase Publishing**
Mobile - 206/669-3053
Phone - 425/869-8724
Toll Free - 800/390-2756
Fax - 425/869-9397

Market Research Analyst: Jordan Zornes
The Next Phase Publishing**
Phone - 425/894-4147
Fax - 425/869-9397

www.MedIntelliBase.com

** A division of Next Phase® Consultancy, Inc.

© The Next Phase® Consultancy, Inc. 2006. All rights reserved.

Return to Top